

Susan E Krown

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8806090/publications.pdf>

Version: 2024-02-01

50
papers

3,277
citations

159585

30
h-index

214800

47
g-index

53
all docs

53
docs citations

53
times ranked

2273
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of treatments for HIV-associated Kaposi sarcoma in Africa. <i>Infectious Agents and Cancer</i> , 2021, 16, 25.	2.6	0
2	Early Progression and Immune Reconstitution Inflammatory Syndrome During Treatment of Mild-To-Moderate Kaposi Sarcoma in Sub-Saharan Africa and South America: Incidence, Long-Term Outcomes, and Effects of Early Chemotherapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 422-429.	2.1	8
3	Clinical Trials for Treatment and Prevention of HIV-Associated Malignancies in Sub-Saharan Africa: Building Capacity and Overcoming Barriers. <i>JCO Global Oncology</i> , 2020, 6, 1134-1146.	1.8	14
4	Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial. <i>Lancet, The</i> , 2020, 395, 1195-1207.	13.7	56
5	Kaposi sarcoma. <i>Nature Reviews Disease Primers</i> , 2019, 5, 9.	30.5	376
6	Cisplatin and radiation therapy in HIV-positive women with locally advanced cervical cancer in sub-Saharan Africa: A phase II study of the AIDS malignancy consortium. <i>Gynecologic Oncology</i> , 2019, 153, 20-25.	1.4	20
7	As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2018, 67, 251-260.	5.8	27
8	Management of AIDS-Related Kaposi's Sarcoma. , 2018, , 1295-1303.		0
9	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 52-57.	2.1	9
10	Stage-Stratified Approach to AIDS-Related Kaposi's Sarcoma: Implications for Resource-Limited Environments. <i>Journal of Clinical Oncology</i> , 2014, 32, 2512-2513.	1.6	10
11	Management of AIDS-Related Kaposi Sarcoma. , 2014, , 139-152.		2
12	Rapamycin With Antiretroviral Therapy in AIDS-Associated Kaposi Sarcoma. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 447-454.	2.1	58
13	Treatment strategies for Kaposi sarcoma in sub-Saharan Africa. <i>Current Opinion in Oncology</i> , 2011, 23, 463-468.	2.4	33
14	Pilot Study of Oral Valganciclovir Therapy in Patients With Classic Kaposi Sarcoma. <i>Journal of Infectious Diseases</i> , 2011, 203, 1082-1086.	4.0	37
15	Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma. <i>Cancer</i> , 2010, 116, 3969-3977.	4.1	138
16	Interferon in Kaposi's Sarcoma Biology and Therapy. , 2010, , 181-198.		1
17	Effects of Chemotherapy in AIDS-Associated Non-Hodgkin's Lymphoma on Kaposi's Sarcoma Herpesvirus DNA in Blood. <i>Journal of Clinical Oncology</i> , 2009, 27, 2496-2502.	1.6	24
18	Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma. <i>Cancer</i> , 2008, 112, 1083-1088.	4.1	15

#	ARTICLE	IF	CITATIONS
19	More on HIV-Associated Kaposi's Sarcoma. <i>New England Journal of Medicine</i> , 2008, 358, 535-536.	27.0	102
20	Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus. <i>Current Opinion in Oncology</i> , 2007, 19, 452-457.	2.4	38
21	AIDS-associated Kaposi's sarcoma: Is there still a role for interferon alfa?. <i>Cytokine and Growth Factor Reviews</i> , 2007, 18, 395-402.	7.2	28
22	Interferon- β With Protease Inhibitor-Based Antiretroviral Therapy in Patients With AIDS-Associated Kaposi Sarcoma. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 41, 149-153.	2.1	42
23	Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain. <i>Cancer</i> , 2006, 107, 1883-1890.	4.1	65
24	Randomized Phase II Trial of Matrix Metalloproteinase Inhibitor COL-3 in AIDS-Related Kaposi's Sarcoma: An AIDS Malignancy Consortium Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 1389-1394.	1.6	154
25	Temozolomide plus thalidomide in patients with brain metastases from melanoma. <i>Cancer</i> , 2005, 103, 2590-2597.	4.1	102
26	Highly Active Antiretroviral Therapy in AIDS-Associated Kaposi's Sarcoma: Implications for the Design of Therapeutic Trials in Patients With Advanced, Symptomatic Kaposi's Sarcoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 399-402.	1.6	135
27	Use of liposomal anthracyclines in Kaposi's sarcoma. <i>Seminars in Oncology</i> , 2004, 31, 36-52.	2.2	128
28	Therapy of AIDS-associated Kaposi's sarcoma: targeting pathogenetic mechanisms. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 763-783.	2.2	39
29	Phase II Study of Temozolomide Plus Thalidomide for the Treatment of Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 3351-3356.	1.6	146
30	Efficacy of Low-Dose Interferon with Antiretroviral Therapy in Kaposi's Sarcoma: A Randomized Phase II AIDS Clinical Trials Group Study. <i>Journal of Interferon and Cytokine Research</i> , 2002, 22, 295-303.	1.2	65
31	Temozolomide Plus Thalidomide in Patients With Advanced Melanoma: Results of a Dose-Finding Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 2610-2615.	1.6	64
32	Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. <i>Aids</i> , 2002, 16, 421-429.	2.2	47
33	Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressive AIDS-Related Kaposi's Sarcoma: An AIDS Clinical Trials Group Clinical Study. <i>Journal of Clinical Oncology</i> , 2002, 20, 3236-3241.	1.6	64
34	Matrix Metalloproteinase Inhibitor COL-3 in the Treatment of AIDS-Related Kaposi's Sarcoma: A Phase I AIDS Malignancy Consortium Study. <i>Journal of Clinical Oncology</i> , 2002, 20, 153-159.	1.6	134
35	Management of Kaposi sarcoma: the role of interferon and thalidomide. <i>Current Opinion in Oncology</i> , 2001, 13, 374-381.	2.4	43
36	Phase II, Randomized, Open-Label, Community-Based Trial to Compare the Safety and Activity of Combination Therapy With Recombinant Interferon- β and Zidovudine Versus Zidovudine Alone in Patients With Asymptomatic to Mildly Symptomatic HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1999, 20, 245-254.	0.3	13

#	ARTICLE	IF	CITATIONS
37	Interferon- α : Evolving Therapy for AIDS-Associated Kaposi's Sarcoma. <i>Journal of Interferon and Cytokine Research</i> , 1998, 18, 209-214.	1.2	30
38	Phase I/II Trial of the Type I Soluble Recombinant Human Interleukin-1 Receptor in HIV-1-Infected Patients. <i>Journal of Interferon and Cytokine Research</i> , 1998, 18, 321-326.	1.2	11
39	Acquired immune deficiency syndrome-related pulmonary non-Hodgkin lymphoma regressing after zidovudine therapy. <i>Cancer</i> , 1993, 71, 2332-2334.	4.1	21
40	Interferon- α 2a in the Treatment of Acquired Immunodeficiency Syndrome-Related Kaposi's Sarcoma. <i>Journal of Immunotherapy</i> , 1991, 10, 39-50.	2.4	66
41	Relationship and Prognostic Value of Endogenous Interferon- α , α 2-Microglobulin, and Neopterin Serum Levels in Patients with Kaposi Sarcoma and AIDS. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 1991, 4, 871-880.	2.1	40
42	Type I interferons (alpha and beta) in HIV disease. <i>Biotherapy</i> (Dordrecht, Netherlands), 1990, 2, 137-147.	0.7	6
43	Interferon- α with Zidovudine: Safety, Tolerance, and Clinical and Virologic Effects in Patients with Kaposi Sarcoma Associated with the Acquired Immunodeficiency Syndrome (AIDS). <i>Annals of Internal Medicine</i> , 1990, 112, 812.	3.9	202
44	Interferons in Malignancy: Biological Products or Biological Response Modifiers?. <i>Journal of the National Cancer Institute</i> , 1988, 80, 306-309.	6.3	30
45	Kaposi's sarcoma and the acquired immune deficiency syndrome. Treatment with recombinant interferon alpha and analysis of prognostic factors. <i>Cancer</i> , 1986, 57, 1662-1665.	4.1	85
46	Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the american cancer society trial. <i>Cancer</i> , 1985, 56, 1305-1310.	4.1	95
47	RECOMBINANT LEUKOCYTE A INTERFERON IN KAPOSI'S SARCOMA. <i>Annals of the New York Academy of Sciences</i> , 1984, 437, 431-438.	3.8	21
48	Preliminary Observations on the Effect of Recombinant Leukocyte a Interferon in Homosexual Men with Kaposi's Sarcoma. <i>New England Journal of Medicine</i> , 1983, 308, 1071-1076.	27.0	358
49	Immunologic reactivity and prognosis in breast cancer. <i>Cancer</i> , 1980, 46, 1746-1752.	4.1	36
50	Intralesional injection of the methanol extraction residue of bacillus calmette-guerin (MER) into cutaneous metastases of malignant melanoma. <i>Cancer</i> , 1978, 42, 2648-2660.	4.1	38